“Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients With Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s403, https://doi.org/10.25251/skin.8.supp.403.